 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 August 1993 | Volume 119 Issue 3 | Pages 199-206
Objective: To identify the best method for determining freedom from disease after gastrinoma resection and for predicting long-term disease-free status in patients with the Zollinger-Ellison syndrome.
Design: Prospective study in consecutive patients.
Setting: Referral-based clinical research center.
Patients: Eighty-one consecutive patients with the Zollinger-Ellison syndrome who underwent surgical exploration for gastrinoma resection.
Intervention: Patients were evaluated after gastrinoma resection, before discharge, 3 to 6 months after surgery, and yearly thereafter. Evaluation included secretin provocative testing and fasting serum gastrin determinations. Follow-up examinations after the initial postoperative evaluations included a clinical assessment, acid secretion studies, a calcium provocative test, and various imaging studies.
Measurements and Main Results: Most patients (96%) had gastrinomas. Freedom from disease was defined by improved symptoms, reduced acid output and antisecretory drug requirements, and a normal gastrin level, normal imaging studies, and negative gastrin provocative studies. Fifty-two percent of patients (n = 42) were disease-free immediately after surgery, 44% at 3 to 6 months, 42% at 1 year, and 35% by 5 years (mean follow-up, 39 months). The secretin provocative test was the first test to become positive in 45% of patients with a recurrence, the serum gastrin determination was the first test to become positive in 36%, and both tests became positive at the same time in 18%. No recurrence was first detected by imaging studies or by calcium provocative testing. Fasting serum gastrin levels and secretin provocative test results at different postoperative times can be used to predict the probability of a patient remaining disease free at 3 years. Patients with a normal gastrin level and a normal secretin provocative test immediately after surgery had a 3-year disease-free probability of 75%, and normal results on both tests at 6 months, 1 year, and 2 years yielded respective probabilities of 88%, 95%, and 100%.
Conclusions: Both the secretin provocative test and fasting serum gastrin determination are necessary for the early diagnosis of cases of recurrent disease after gastrinoma resection. The calcium provocative test and imaging studies do not detect any recurrences first. Fasting serum gastrin determinations and secretin provocative testing at different postoperative times can be used to predict the probability of a patient remaining disease free at 3 years.
Author and Article Information
From the National Institutes of Health, Bethesda, Maryland.
ARTICLE
Assessment and Prediction of Long-term Cure in Patients with the Zollinger-Ellison Syndrome: The Best Approach
Requests for Reprints: Robert T. Jensen, MD, National Institutes of Health, Building 10, Room 9C-103, Bethesda, MD 20892.
This article has been cited by other articles:
|
|
 |
|
  S. H. Long, M. J. Berna, M. Thill, A. Pace, T. K. Pradhan, K. M. Hoffmann, J. Serrano, and R. T. Jensen Secretin-Receptor and Secretin-Receptor-Variant Expression in Gastrinomas: Correlation with Clinical and Tumoral Features and Secretin and Calcium Provocative Test Results J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4394 - 4402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Hoffmann, F. Gibril, L. K. Entsuah, J. Serrano, and R. T. Jensen Patients with Multiple Endocrine Neoplasia Type 1 with Gastrinomas Have an Increased Risk of Severe Esophageal Disease Including Stricture and the Premalignant Condition, Barrett's Esophagus J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Panzuto, S. Nasoni, M. Falconi, V. D. Corleto, G. Capurso, S. Cassetta, M. Di Fonzo, V. Tornatore, M. Milione, S. Angeletti, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization Endocr. Relat. Cancer, December 1, 2005; 12(4): 1083 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Asgharian, M. L. Turner, F. Gibril, L. K. Entsuah, J. Serrano, and R. T. Jensen Cutaneous Tumors in Patients with Multiple Endocrine Neoplasm Type 1 (MEN1) and Gastrinomas: Prospective Study of Frequency and Development of Criteria with High Sensitivity and Specificity for MEN1 J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5328 - 5336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Asgharian, Y.-J. Chen, N. J. Patronas, P. L. Peghini, J. C. Reynolds, A. Vortmeyer, Z. Zhuang, D. J. Venzon, F. Gibril, and R. T. Jensen Meningiomas May Be a Component Tumor of Multiple Endocrine Neoplasia Type 1 Clin. Cancer Res., February 1, 2004; 10(3): 869 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Norton, M. Kivlen, M. Li, D. Schneider, T. Chuter, and R. T. Jensen Morbidity and Mortality of Aggressive Resection in Patients With Advanced Neuroendocrine Tumors Arch Surg, August 1, 2003; 138(8): 859 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gibril, Y.-J. Chen, D. S. Schrump, A. Vortmeyer, Z. Zhuang, I. A. Lubensky, J. C. Reynolds, A. Louie, L. K. Entsuah, K. Huang, et al. Prospective Study of Thymic Carcinoids in Patients with Multiple Endocrine Neoplasia Type 1 J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1066 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Chen, A. Vortmeyer, Z. Zhuang, S. Huang, and R. T. Jensen Loss of Heterozygosity of Chromosome 1q in Gastrinomas: Occurrence and Prognostic Significance Cancer Res., February 15, 2003; 63(4): 817 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. U. Goebel, M. Iwamoto, M. Raffeld, F. Gibril, W. Hou, J. Serrano, and R. T. Jensen HER-2/neu Expression and Gene Amplification in Gastrinomas: Correlations with Tumor Biology, Growth, and Aggressiveness Cancer Res., July 1, 2002; 62(13): 3702 - 3710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Peghini, M. Iwamoto, M. Raffeld, Y.-J. Chen, S. U. Goebel, J. Serrano, and R. T. Jensen Overexpression of Epidermal Growth Factor and Hepatocyte Growth Factor Receptors in a Proportion of Gastrinomas Correlates with Aggressive Growth and Lower Curability Clin. Cancer Res., July 1, 2002; 8(7): 2273 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gibril, D. J. Venzon, J. V. Ojeaburu, S. Bashir, and R. T. Jensen Prospective Study of the Natural History of Gastrinoma in Patients with MEN1: Definition of an Aggressive and a Nonaggressive Form J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5282 - 5293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. U. Goebel, P. L. Peghini, P. K. Goldsmith, A. M. Spiegel, F. Gibril, M. Raffeld, R. T. Jensen, and J. Serrano Expression of the Calcium-Sensing Receptor in Gastrinomas J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4131 - 4137. [Abstract] [Full Text]
|
|
|
|
|
|
J. Serrano, S. U. Goebel, P. L. Peghini, I. A. Lubensky, F. Gibril, and R. T. Jensen Alterations in the p16INK4a/CDKN2A Tumor Suppressor Gene in Gastrinomas J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4146 - 4156. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Gibril, J. C. Reynolds, I. A. Lubensky, P. K. Roy, P. L. Peghini, J. L. Doppman, and R. T. Jensen Ability of Somatostatin Receptor Scintigraphy to Identify Patients with Gastric Carcinoids: A Prospective Study J. Nucl. Med., October 1, 2000; 41(10): 1646 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. U. Goebel, C. Heppner, A. L. Burns, S. J. Marx, A. M. Spiegel, Z. Zhuang, I. A. Lubensky, F. Gibril, R. T. Jensen, and J. Serrano Genotype/Phenotype Correlation of Multiple Endocrine Neoplasia Type 1 Gene Mutations in Sporadic Gastrinomas J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 116 - 123. [Abstract] [Full Text]
|
|
|
|
|
|
S. U. Goebel, A. O. Vortmeyer, Z. Zhuang, J. Serrano, R. T. Jensen, and I. A. Lubensky Identical Clonality of Sporadic Gastrinomas at Multiple Sites Cancer Res., January 1, 2000; 60(1): 60 - 63. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. A. Norton, D. L. Fraker, H. R. Alexander, D. J. Venzon, J. L. Doppman, J. Serrano, S. U. Goebel, P. L. Peghini, P. K. Roy, F. Gibril, et al. Surgery to Cure the Zollinger-Ellison Syndrome N. Engl. J. Med., August 26, 1999; 341(9): 635 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Yu, D. J. Venzon, J. Serrano, S. U. Goebel, J. L. Doppman, F. Gibril, and R. T. Jensen Prospective Study of the Clinical Course, Prognostic Factors, Causes of Death, and Survival in Patients With Long-Standing Zollinger-Ellison Syndrome J. Clin. Oncol., February 1, 1999; 17(2): 615 - 615. [Abstract] [Full Text] [PDF]
|
|
Article
